Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia

Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist as significant challenges. Recent studies have uncovered role...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Adv
Main Authors: Maharaj, Kamira, Powers, John J., Achille, Alex, Deng, Susan, Fonseca, Renee, Pabon-Saldana, Mibel, Quayle, Steven N., Jones, Simon S., Villagra, Alejandro, Sotomayor, Eduardo M., Sahakian, Eva, Pinilla-Ibarz, Javier
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2018
Teme:
Immunobiology and Immunotherapy
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6234358/
https://ncbi.nlm.nih.gov/pubmed/30425065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018020065
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki